Dec 04, 2021 / 04:30AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the conference call of Eris Lifesciences. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. V. Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you, and over to you, sir.
Krishnakumar Vaidyanathan - Eris Lifesciences Limited - Executive Director & COO
Good morning. I'm happy to share with you today that Eris has announced its entry into India's insulin and GLP-1 agonist market through Eris MJ Biopharm Limited, a special purpose joint venture between Eris and Mumbai-based MJ Biopharm Private Ltd. The insulin and GLP-1 market in India is presently worth INR 3,500 crores to INR 4,000 crores, and we expect that to double over the next 5 years. So we are talking of an addressable market of nearly INR 8,000 crores by the year 2025, '26.
Eris, one of India's leading players in the overall diabetes care segment, will now extend its product offering to insulin and GLP-1 agonist. The 70-30 joint venture,
Eris Lifesciences Ltd To Discuss Joint Venture with Mj Biopharm Pvt Ltd Call Transcript
Dec 04, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers